Expert View: Eshmuno® CP-FT resin – developed for the flow-through removal of aggregates using frontal chromatography
Posted: 28 June 2019 | Merck | No comments yet
Eshmuno® CP-FT cation exchange resin is specifically designed to provide efficient removal of monoclonal antibody (mAb) aggregates in the flow-through frontal chromatography mode of operation enabling loading capacities 10-times higher than traditional bind/elute CEX chromatography. It facilitates greater manufacturing flexibility and process intensification while reducing the overall cost for the downstream purification of mAbs.
MAbs are a successful class of therapeutic proteins increasingly used in the biopharmaceutical industry, but the manufacture of safe and effective mAb drug products as well as increasing productivities of upstream processes provides many challenges to downstream purification.
The rest of this content is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- bi-monthly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Issue
Related topics
Biopharmaceuticals, Bioprocessing, Bioproduction, Chromatography, Downstream, Proteins, QA/QC
